Beximco Pharmaceuticals PLC. (BST:R2WA)

Market Cap	355.45M +25.5%
Revenue (ttm)	373.79M +11.3%
Net Income	51.25M +29.2%
EPS	0.11 +29.2%
Shares Out	n/a
PE Ratio	6.94
Forward PE	7.27
Dividend	0.02 (5.20%)
Ex-Dividend Date	Nov 22, 2024

Volume	1,200
Average Volume	740
Open	0.4660
Previous Close	0.4660
Day's Range	0.4640 - 0.4760
52-Week Range	0.3700 - 0.7900
Beta	n/a
RSI	49.41
Earnings Date	Jan 27, 2026

About BST:R2WA

Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to oth...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 1,122
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: R2WA

Financial Performance

In fiscal year 2024, BST:R2WA's revenue was 44.39 billion, an increase of 13.05% compared to the previous year's 39.27 billion. Earnings were 5.83 billion, an increase of 26.34%.

Financial numbers in BDT